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Abstract: Background: PHACE syndrome is a rare inborn condition characterized by large facial he-
mangiomas and variable malformations of the arterial system, heart, central nervous system, and eyes.
According to Orphanet estimates, the prevalence is <1.0 per million. Data from Europe are limited to
small case series, and there are no population-based data available. Objectives: We conducted the present
study to provide population-based estimates of the disease prevalence of PHACE syndrome in children
in Germany, Switzerland, and Austria. We compared these first systematic data on PHACE syndrome
from Europe to published data from the PHACE Syndrome International Clinical Registry and Genetic
Repository (USA). Clinical features in our cohort with PHACE syndrome were assessed in detail, includ-
ing the need for early supportive measures. Methods: We used a population-based approach by means of
a previously well-established network of child neurologists from Germany, Switzerland, and Austria (“ES-
NEK”) to identify potential patients. The patients’ guardians and child neurologists were asked to fill in
questionnaires developed in collaboration with the International PHACE Registry. Results: We identi-
fied 19 patients with PHACE syndrome. Estimated prevalence rates were 6.5 per million in Switzerland,
0.59 per million in Germany, and 0.65 per million in Austria. A subset of 10 patients from Germany and
Switzerland participated in our study, providing detailed clinical assessment (median age: 2.5 years; 9
females, 1 male). Cerebrovascular involvement was frequent (80%). Facial hemangioma extent correlated
significantly with the number of organs involved (p = 0.011). In 9 out of 10 patients, facial heman-
giomas were treated successfully with oral propranolol. Baseline demographic data as well as the rate of
cerebrovascular and cardiovascular anomalies were in line with those from the US International PHACE
Registry and other published PHACE cohorts. Conclusions: Our study provides population-based esti-
mates for PHACE syndrome in 3 German-speaking countries. The data from Switzerland indicate that
PHACE syndrome may be more prevalent than demonstrated by previous reports. Underreporting of
PHACE syndrome in Germany and Austria likely accounts for the differences in prevalence rates. The
clinical observation of a potential association between the size of facial hemangioma and extent of organ
involvement warrants further investigation.
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Abstract
Background: PHACE syndrome is a rare inborn condition 
characterized by large facial hemangiomas and variable mal-
formations of the arterial system, heart, central nervous sys-
tem, and eyes. According to Orphanet estimates, the preva-
lence is <1.0 per million. Data from Europe are limited to 
small case series, and there are no population-based data 
available. Objectives: We conducted the present study to 
provide population-based estimates of the disease preva-
lence of PHACE syndrome in children in Germany, Switzer-
land, and Austria. We compared these first systematic data 
on PHACE syndrome from Europe to published data from the 
PHACE Syndrome International Clinical Registry and Genetic 
Repository (USA). Clinical features in our cohort with PHACE 
syndrome were assessed in detail, including the need for 
early supportive measures. Methods: We used a population-
based approach by means of a previously well-established 
network of child neurologists from Germany, Switzerland, 
and Austria (“ESNEK”) to identify potential patients. The pa-
tients’ guardians and child neurologists were asked to fill in 
questionnaires developed in collaboration with the Interna-
tional PHACE Registry. Results: We identified 19 patients 
with PHACE syndrome. Estimated prevalence rates were 6.5 
per million in Switzerland, 0.59 per million in Germany, and 
0.65 per million in Austria. A subset of 10 patients from Ger-
many and Switzerland participated in our study, providing 
detailed clinical assessment (median age: 2.5 years; 9 fe-
males, 1 male). Cerebrovascular involvement was frequent 
(80%). Facial hemangioma extent correlated significantly 
with the number of organs involved (p = 0.011). In 9 out of 
10 patients, facial hemangiomas were treated successfully 
with oral propranolol. Baseline demographic data as well as 







































































were in line with those from the US International PHACE Reg-
istry and other published PHACE cohorts. Conclusions: Our 
study provides population-based estimates for PHACE syn-
drome in 3 German-speaking countries. The data from Swit-
zerland indicate that PHACE syndrome may be more preva-
lent than demonstrated by previous reports. Underreport-
ing of PHACE syndrome in Germany and Austria likely 
accounts for the differences in prevalence rates. The clinical 
observation of a potential association between the size of 
facial hemangioma and extent of organ involvement war-
rants further investigation. © 2020 S. Karger AG, Basel
Introduction
The acronym PHACE(S) (OMIM 606519) designates 
a rare, inborn condition comprising malformations of the 
posterior fossa of the brains (P), large segmental facial 
hemangiomas (H), and variable involvement of other or-
gans such as anomalies of the arterial system (A), the 
heart (cor, C), the eyes (E), and sternal defects (S) [1]. 
Specific patterns of facial hemangioma corresponding to 
embryonic facial prominences, persistence of embryonic 
vessels, and arterial anomalies including aberrant course 
or origin point toward a defect in early embryogenesis 
[2]. In a study evaluating 108 infants with large segmental 
facial hemangioma, approximately every third patient 
was diagnosed with PHACE syndrome [3]. According to 
Orphanet estimates, the prevalence is <1/1,000,000 [4]. 
Yet, population-based data are scarce and, to the best of 
our knowledge, no studies on the prevalence of PHACE 
syndrome have been conducted in Europe so far. We used 
a network of child neurologists to study the epidemiology 
and clinical features of PHACE syndrome in Germany, 
Switzerland, and Austria [5].
Materials and Methods
A Multinational Study in Germany, Switzerland, and Austria
We conducted a multinational survey in the 3 German-speak-
ing countries Germany, Switzerland, and Austria, using a pre-ex-
isting network of child neurologists (“ESNEK,” i.e., in German 
“Erhebung Seltener Neurologischer Erkrankungen im Kindesal-
ter”; English translation “Acquisition of Rare Neurological Disor-
ders in Childhood”) [5]. ESNEK is a well-established network of 
child neurologists in the German-speaking countries Germany, 
Switzerland, and Austria. It is located at University Medical Center 
Göttingen, Germany. Through the network, all registered child 
neurologists from Germany, Switzerland, and Austria were con-
tacted by email to recruit potential pediatric patients with the rare 
neurologic condition under investigation. This mailing list, which 
is continuously being updated, includes approximately 1,700 email 
addresses. Among these, 70 addresses each are from Swiss and 
from Austrian child neurologists, respectively. The child neurolo-
gists were asked to send an email response with just the case num-
bers of patients with PHACE syndrome or Sturge-Weber syn-
drome (SWS) in their medical attendance, if any. They were not 
asked to respond if they did not care for any such patients.
Orphanet is a well-established platform and reference source 
for rare diseases. It is a freely accessible network of 41 countries, 
coordinated at the INSERM in Paris. The network was founded in 
France and it is still funded by the INSERM, the French Ministry 
of Health, and by the European Commission [6]. It provides in-
sights not only on the characteristics of rare diseases itself but also 
on current research, orphan drugs, patient organizations, expert 
networks, and diagnostic tests.
For this study, we included all patients with a definitive clinical 
diagnosis of PHACE syndrome. In a parallel study arm, we simul-
taneously recruited patients with SWS, that is, a similar, but more 
well-known phacomatosis, to identify potentially unrecognized/
confounded cases of PHACE syndrome from the SWS cohort. The 
referring physicians included a broad range of child neurologists, 
operating in private practices to tertiary referral centers, for ex-
ample, university hospitals. Among all registered collaboration 
partners, 11 child neurologists from Germany, Switzerland, and 
Austria identified suitable patients with PHACE syndrome. One 
patient was self-reported by his guardians; 2 patients were diag-
nosed and recruited by SD (one of the 2 latter patients was report-
ed previously [7]).
The study protocol was approved by the responsible Institu-
tional Review Board in Saarbrücken, University of Saarland, Ger-
many (ID: 209/17, October 2017), for all patients. All included pa-
tients’ legal guardians provided informed consent. The study was 
registered in the German Clinical Trials Registry (ID: DRKS 
00013551, UTN U1111-1206-9923).
Case Definitions and Inclusion Criteria
As a case definition, we used the international criteria for 
PHACE syndrome published in 2009 by a multidisciplinary con-
sensus group of physicians [8] with adaption following analysis of 
a high-risk cohort of pediatric patients with large facial hemangi-
oma [3]. Accordingly, patients aged <18 years at time of study in-
clusion with a large facial hemangioma >5 cm in diameter and 1 
major criterion or 2 minor criteria were enrolled. Study enrollment 
started in January 2018 and comprised all pediatric patients with 
clinically established PHACE syndrome up to December 2018. 
Cases were only included after clinical diagnosis of PHACE syn-
drome was confirmed using medical records and/or question-
naires.
Data Assessment and Clinical Variables
We used 2 different, partially modified, translated, and profes-
sionally retranslated versions of a questionnaire developed by the 
PHACE registry in Wisconsin, USA, to ensure comparability to 
existing databases (see Appendix for the questionnaires used in 
this study). The PHACE Syndrome International Clinical Registry 
and Genetic Repository is a research registry located at Children’s 
Hospital of Wisconsin in the city of Milwaukee, Wisconsin, USA. 
Patients were enrolled into the registry from November 18, 2010, 









































































Thus, the registry covered a pediatric population of 79.8 million 
children (as of 2017/2018) [10, 11]. So far, 218 patients have been 
enrolled in the registry [9]. One questionnaire was designed for the 
patients’ families, the other for the patients’ child neurologists. 
While the original questionnaire version for child neurologists in-
cluded only assessment of PHACE criteria, we added questions on 
perinatal risk factors, family history, current symptoms, neuro-
logic involvement, and organ involvement as well as questions on 
therapies and therapeutic success. The family questionnaires in-
cluded patients’ histories and their parents’ histories, ethnicity, 
perinatal factors, descriptions of the phenotype including PHACE 
criteria, and organ involvement as well as development, feeding, 
and use of the healthcare system. Furthermore, we asked the fam-
ilies about diagnostic procedures including genetic analyses, cur-
rent clinical symptoms, surgeries, medication and hemangioma 
treatment, and need for early supportive measures (physical ther-
apy, occupational therapy, special education services, and speech 
and language therapy).
Statistical Methods
We first performed standard descriptive statistics. If normally 
distributed, we used mean/standard deviation to describe con-
tinuous variables and median/interquartile ranges for other dis-
tributions. For categorical variables, we indicated absolute and 
relative frequencies. Exploratory analyses were used to assess po-
tential associations between covariates. The results of descriptive 
statistics were compared to published data from the International 
PHACE registry and to other PHACE cohorts. Current data on 
the pediatric populations from Germany, Switzerland, and Aus-
tria were extracted from public electronic databases [12–16]. For 
calculation of prevalence rates, standard epidemiologic proce-
dures were used. One-year-period prevalence rates for PHACE 
syndrome in Germany, Switzerland, and Austria in 2018 were cal-
culated, using midyear populations under risk. We used midyear 
populations because this procedure minimizes error due to 
changes in the population occurring during the course of 1 year. 
As the assumptions of independent disease occurrence and ho-
mogeneity of risks for the individual patients were fulfilled, we 
used a binomial distribution to determine confidence intervals of 
prevalence rates [17]. More specifically, we used the binconf func-
tion from the Hmisc package in R 3.5.3 to calculate Wilson score 
test-based confidence intervals. All analyses were conducted with 
Microsoft Excel 2013 (descriptive statistics) and R 3.5.3. (data 
analysis).
Results
We received notifications of 19 cases with clinically 
diagnosed PHACE syndrome (8 from Germany, 10 from 
Switzerland, and 1 from Austria). 10 cases consented to 
participate in our study and completed both the families’ 
and the child neurologists’ questionnaires (52.6%). In all 
patients, we critically reviewed the detailed question-
naires which included descriptions of facial hemangioma 
and vascular anomalies as well as all other PHACE crite-
ria to confirm the diagnosis. In 60%, we additionally re-
ceived copies of medical records including imaging stud-
ies and descriptions/photos of facial hemangioma. One of 
our cases with PHACE syndrome had been confounded 
previously with SWS, but the diagnosis had been correct-
ed prior to this study.
Patient Characteristics
All patients fulfilled the current criteria for “definite 
PHACE syndrome” [3]. At inclusion in our study, the pa-
tients’ ages were between 10 months and 9 years. All pa-
tients were born in Europe and were unrelated. In accor-
dance with previous reports, for example, [18], we includ-
ed arachnoid cysts as posterior fossa involvement. 
Patients’ characteristics are summarized in Table 1.
Prevalence Rate of PHACE Syndrome in Germany, 
Switzerland, and Austria
All prevalence rates were calculated based on the total 
number of notifications by the collaborating pediatri-
cians, independent of study participation. Overall preva-
lence rates were 0.59/million (95% CI: 0.299–1.164/mil-
lion) in Germany and 0.65/million (95% CI: 0.033–3.693/
million) in Austria, but 10-fold higher in Switzerland 
(6.57/million) (95% CI: 3.571–12.103/million).
Table 1. Characteristics of PHACE syndrome patients




Current age in years 
(median, IQR; range)
2.5 (1.75); 
10 months to 9 years
Race
Caucasian 9 (90)






Posterior fossa 4 (40)
(Facial) Hemangioma 10 (100)
Arterial (cerebrovascular) anomalies 8 (80)
Cardiovascular anomalies 5 (50)
Eye anomalies 3 (30)
Sternal defect 1 (10)
Absolute and relative frequencies are indicated for categorical 
variables. For the numerical variable, median, interquartile range, 







































































Due to predominance of younger children (<5 years) 
in the German subcohort, we calculated age-specific 
prevalence rates for Germany and Switzerland. Swiss age-
specific prevalence for children aged 0–5 years yielded 
5.77/million (95% CI: 1.963–16.975); thus, the age-specif-
ic rate showed to be comparable to the overall Swiss prev-
alence rate. Age-specific prevalence in German children 
of 0–5 years of age was significantly higher than the over-
all prevalence: 1.08/million (95% CI: 0.462–2.532).
PHACE Criteria in This Patient Cohort
Table  2 provides an overview of the patients’ major 
and minor criteria for PHACE syndrome [3]. Most pa-
tients showed facial hemangioma and at least one cere-
Table 2. PHACE criteria including MRI characteristics and facial hemangioma localization in this cohort, as well as localization of extra 





Major criteria (additional to facial 
hemangioma)







1 (D) f, 3 Left unilateral cerebellar hypoplasia; 
hypoplasia left ICA, prox. CCA




2 (D) f, 1 Right unilateral cerebellar hypoplasia; 
hypoplasia right ICA






f: difficulties as infant
3 (D) f, 2 Persistent trigeminal artery; anomalous 
origin and course of left CCA, anomalous 
origin of right CCA, anomalous right ICA 
supplied by right vertebral artery
Right aortic 
arch









Segments 4 (nose 
only), 1L, 2L, 3L
None d: delayed speech, speech hard 
to understand as a toddler, 
required physical and 
occupational therapy; attends 
a regular school
f: normal




6 (CH) f, 2 Left cerebellar hypoplasia and dysplasia; 
hypoplasia left CCA, ECA, vertebral 
artery; aplasia left ICA; dysplasia right 
ICA
n/a Segments 1L, 2L None d: slight developmental delay; 
requires physical therapy
f: normal
7 (CH) f, 10 
months
Aortic coarctation n/a Segments 2R; 3R Cheek 
intraorally, 
palate, frenulum
d: speech n/a (too young); 
otherwise normal
f: suckling difficulties
8 (D) f, 2 Sternal cleft n/a Segments 2R; 3R; 2L, 
lips/mouth, left auricle
Right arm d: requires physical therapy
f: normal
9 (CH) f, 7 Left ICA severe stenosis, in further 
course ectasia, elongation, multiple 
kinking, dilatation PCA; left optic nerve 
atrophy
Left coloboma Segments L1; L2; L3 Left tympanic 
membrane
d: requires physical therapy
f: feeding difficulties due to 
ulceration of lip
10 (D) f, 4 Anomalous, partially aplastic left ICA, 
hypoplasia right vertebral artery; bundle-
like convolute of vessels in head of basilar 
artery; aortic coarctation
n/a Segments 1L; 4 Back d: normal
f: slow drinking









































































brovascular malformation. Posterior fossa anomalies 
were recorded in 4/10 cases (40%). One patient showed a 
sternal defect and thus can be classified as “PHACES” 
syndrome.
Facial Hemangioma and Organ Involvement
Facial hemangioma involved between 2 and 4 of the 
previously described facial segments. Two patients (20%) 
showed bilateral hemangioma (excluding the midline 
segment 4). Aside of facial hemangioma, 7 patients (70%) 
showed an additional extra facial hemangioma (Table 2). 
Other clinical features were congenital hypothyroidism 
(due to agenesis of the thyroid gland), ulcerations of the 
lip and nose, and idiopathic thrombocytopenia. In this 
sample of young patients, severe headaches were reported 
in one case. None of the patients suffered from involve-
ment of gastrointestinal organs, respiratory problems, or 
acute ischemic stroke (AIS).
We assessed a potential association between the num-
ber of segments affected by the facial hemangioma (as 
reported by the patients’ child neurologists) and organ 
involvement (e.g., eyes, brains, and arterial system). As 
shown in Figure 1, the number of involved organ systems 
increased significantly with the number of segments af-
fected by facial hemangioma (rho = 0.755; p = 0.011).
Feeding, Sensory Organs, and Development
Table  3 gives an overview of the patients’ impair-
ment, course of disease, and use of supportive therapies. 
Many caregivers reported feeding difficulties as infants 
(n = 5), the reasons ranging from ulceration of perioral 
hemangioma to suckling difficulties. However, none of 
these difficulties were persistent or severe as none re-
quired a feeding tube, and none had failure to thrive. 
Speech development was normal in all cases but one. 
Multiple patients received physical therapy (n = 4), and 
one additionally had occupational therapy. Slight devel-
opmental delay was documented in 1 case, but none re-
quired early supportive measures. None of our patients 
suffered from seizures, and none required neurosurgery. 
Hearing problems were described in 2 cases, probably 
due to multiple ear infections. Ophthalmologic symp-
toms were relatively frequent in this cohort (n = 5) and 
comprised (1) 1 case of amblyopia and ptosis contralat-
eral to facial hemangioma, ipsilateral to intraorbital 
hemangioma; (2) 1 case of coloboma and optic nerve 
atrophy resulting in reduced visual acuity, (3) 1 case of 
increased intraocular pressure, and (4, 5) 2 cases of tran-
sient limitations to open the eye due to periocular hem-
angioma.
Therapy and Therapeutic Outcome
As a treatment for facial hemangioma, all patients 
were administered oral propranolol. Treatment was usu-
ally initiated within the first 1.5 months of life. In 2 cases, 
propranolol was first given at the age of 3 months and 1.0 
years, respectively. All cases but one reported good suc-
cess of hemangioma treatment, and one indicated moder-
ate success (late treatment start was not associated with a 
worse outcome in this cohort). Usually, a dosage of 2 mg/
kg was used. One case received additional laser therapy. 
None of the patients required antiepileptic drugs or neu-
























Fig. 1. Association between number of seg-
ments affected by facial hemangioma and 
number of involved organ systems per pa-








































































To the best of our knowledge, this is the first study to 
provide systematic data on PHACE syndrome in Europe, 
including Germany, Switzerland, and Austria. We calcu-
lated prevalence rates, based on 19 patients identified by 
systematic acquisition through an email-based network 
of child neurologists. Assessment of clinical features as 
well as data on diagnostic and therapeutic procedures was 
based on 10 patients (52.6%) of our study cohort who sent 
back complete questionnaires.
Discussion of Prevalence Rates
Substantial differences in the prevalence rates were 
seen between Switzerland (approx. 10-fold higher preva-
lence rate) on one hand and Austria and Germany on the 
other hand. This was most likely caused by differences in 
diagnosis, treatment and follow-up of patients as well as 
by differences in the administrative infrastructure for pa-
tients with PHACE syndrome between the 3 countries. 
Although we used a well-established network for rare 
neurologic disorders, underreporting has to be taken into 
consideration. It may be caused by both “diagnostic bias” 
as well as “reporting bias”: While undiagnosed cases es-
cape every reporting system, bias due to nonreported cas-
es may be discerned using the Capture-Recapture meth-
od [19]. In another well-established German Surveillance 
Tool for rare diseases, ESPED (“Erhebungseinheit für Sel-
tene Pädiatrische Erkrankungen in Deutschland”), com-
pleteness of registration for this nonmandatory reporting 
system has been evaluated and yielded completeness rates 
between 60 and 70% for childhood diabetes mellitus [20] 
and 25% for children hospitalized due to infection with 
pertussis [21]. Using the “Capture-Recapture” method, 
an underreporting rate due to “reporting bias” of 56% has 
been calculated for multiple sclerosis in children and ad-
olescents [22]. However, this method requires a second, 
independent data source – which was not available in our 
study for PHACE syndrome. As a last aspect, the increas-
ing number of publications on PHACE syndrome in the 
past decade (e.g., in Pubmed) makes it plausible that 
awareness of physicians for this rare phacomatosis has 
increased, probably leading to an increase in the number 
of diagnosed cases. This may explain the lower prevalence 
rate in the Orphanet report (last update 2007).
Demographic Features
The median age in our cohort was 2.5 years, and we 
found a strong female preponderance of 90%, findings 
that are compatible with previous reports [9, 23–26]: An 
identical female-to-male ratio of 9:1 had been observed in 
one of the early PHACE Syndrome Patient Registry re-
ports [26], and another smaller cohort was composed 
only of females [23]. The proportion of females in larger 
PHACE cohorts varied between 80.3% [9] and 88% [24]. 
The only male patient of our cohort showed rather severe 
involvement with extensive facial hemangioma, several 
cerebrovascular malformations, speech delay, and articu-
lation difficulties as a toddler. Still, previous investiga-
tions have shown no hint toward X-linked inheritance as 
indicated by a study on X-chromosome inactivation pat-
terns [27] or toward differences in prenatal history be-
tween the sexes [9]. To date, the reasons for female pre-
dominance in PHACE syndrome remain to be elucidat-
ed. Regarding ethnicity, this cohort and previous reports 
indicate that PHACE syndrome is most prevalent in Cau-
Table 3. Impairment, course of disease, and use of supportive 
therapies
Patient characteristics (n = 10) N (%)
Feeding
Any feeding difficulties as infant 5 (50)
Required tube feeding 0 (0)
Failure to thrive 0 (0)
Age (months) when child drinks liquids from a 
cup (mean, SD; not reported n = 4) 11.2 (4.5)
Ophthalmologic symptoms
External, due to facial hemangioma 2 (20)
Other malformations 3 (30)
Hearing problems
Normal newborn hearing screening 9 (90)
Multiple ear infections or “glue” ear 2 (20)
Sensorineural hearing loss 0 (0)
Speech development
Any delay 1 (10)
Age (months) when child starts to babble 
(median, IQR; not reported n = 2) 8 (1.5)
Difficulties to understand spoken language 1 (10)
Speech was/is hard to understand 1 (10)
Seizures 0 (0)
Supportive therapies
Early supportive measures 0 (0)
Physical therapy 4/10 (40)
Occupational therapy 1/10 (10)
Special education services 0 (0)
Speech and language therapy (not reported n = 1) 0 (0)
Headaches/Migraine 1 (10)
Absolute and relative frequencies are indicated for categorical 
variables. For numerical variables, depending on data distribution, 










































































casians [3, 9] while other races are less commonly affect-
ed.
Cerebrovascular involvement is known to be the most 
common extracutaneous anomaly in PHACE syndrome 
[3]. In a prospective multicenter cohort study in 108 pa-
tients with large facial hemangiomas including 33 infants 
with PHACE syndrome, the prevalence of cerebrovascu-
lar anomalies was 91% [3]. A case series and review of 115 
PHACE cases detected cerebral vascular anomalies [25] in 
77.4% of the cases. Due to recruitment of our cohort via a 
network of child neurologists, one could have suspected 
an increased rate of malformations of the cerebral vascu-
lature, but the rate was 80% and it is thus in line with pre-
vious reports which indicates that no recruitment bias was 
introduced. Cerebrovascular anomalies described in 
PHACE syndrome include a wide range of arterial malfor-
mations such as dysplasia, hypoplasia, or aplasia of cere-
bral arteries; stenosis or occlusion of the cerebral arteries; 
aberrant origin or course of the cerebral arteries; and per-
sistence of embryonic arteries [3]. PHACE syndrome with 
abnormalities of cardiovascular and cerebral arteries pos-
es an elevated risk for acute stroke. While no acute neuro-
logic events were recorded in our cohort, a review of 22 
pediatric patients [28] with PHACE syndrome and AIS 
showed that aplasia, hypoplasia, or occlusion of at least 1 
cerebral artery, additional aortic arch anomalies, and 
medication with corticosteroids were major risk factors. 
Notably, all patients with PHACE syndrome and AIS who 
reported their medication exposure (i.e., 64% of this co-
hort) had been treated with corticosteroids [28]. Accord-
ing to current guidelines, due to potential side effects, sys-
temic corticosteroids are only applied in emergencies or 
refractory situations, for example, respiratory distress in 
airway hemangioma (see below) [29]. Counseling of care-
givers and medical staff of patients with PHACE syn-
drome with regard to typical symptoms of AIS (new hemi-
paresis and new seizures) [28] and unspecific symptoms 
of AIS (irritability and lethargy) [30] may be beneficial. 
Prothrombotic laboratory workup was positive in only a 
single patient from 2 published case series of patients with 
PHACE syndrome and AIS [28, 31], making concomitant 
coagulopathies in PHACE syndrome unlikely. Following 
recommendations by an expert panel, antiplatelet pro-
phylaxis with acetylsalicylic acid (4–5 mg/kg) should 
be considered in asymptomatic high-risk patients [32], 
and – under careful monitoring for signs of bleeding – 
it has been used successfully following acute stroke in a 
small case series of infants with PHACE syndrome [31].
Cardiovascular malformations include anomalies of 
the heart, aorta, and brachiocephalic vessels. The largest 
study in PHACE patients which investigated cardiovas-
cular anomalies comprised 150 patients from the Inter-
national PHACE Syndrome Registry and reported 41% of 
PHACE cases to be affected [33]. In a smaller study in-
cluding infants with large facial hemangioma, 67% of 
PHACE patients showed any cardiovascular anomaly [3]. 
Thus, 50% cardiovascular anomalies in our cohort are in 
line with data from the literature. As also reflected in our 
cohort, aortic coarctation is frequent in PHACE syn-
drome and often necessitates interventional or surgical 
repair. Bayer et al. [33] identified distinct patterns with 
regard to aortic coarctation location and histopathologic 
features in patients with PHACE syndrome; these find-
ings point toward unique etiopathologies when com-
pared to classic aortic coarctation. The high rate of car-
diovascular malformation underpins the importance of 
thorough imaging studies in patients evaluated for 
PHACE syndrome.
Few studies have addressed neurologic symptoms and 
sequelae as well as the need for medical supportive mea-
sures in children with PHACE syndrome. While the prev-
alence of developmental delays is unclear, various anom-
alies have been reported: gross and fine motor delays [34], 
speech and language delays, [18, 34], dysphagia [35], and 
early-onset migrainous headaches [36]. In our cohort, as 
many as 50% of all cases reported feeding difficulties as 
an infant, but none required the use of a feeding tube and 
none had failure to thrive. Speech and language delays 
were reported rarely in our cohort, yet this may be due to 
the young age of the included patients (median age: 2.5 
years). Many patients of our cohort required physical 
therapy, a finding compatible with (usually mild) gross 
motor developmental delays reported previously [34]. To 
summarize, close clinical/neurologic follow-up including 
monitoring of nutritional status is important in all pa-
tients with PHACE syndrome.
Segmental facial hemangioma, the hallmark in PHACE 
syndrome, contributes to the patients’ morbidity but may 
also be life-threatening, for example, in airway heman-
gioma. Potential local complications of facial hemangio-
ma include ulcerations with bleeding, amblyopia in cases 
blocking the visual axis, and feeding difficulties in peri-
oral hemangioma. Laryngoscopic and bronchoscopic 
evaluation to rule out airway hemangioma is recom-
mended in every patient with respiratory symptoms or 
extensive facial hemangioma in the beard localization [2, 
37]. In the past, different types of treatment for large facial 
hemangioma have been recorded in PHACE syndrome, 
including systemic steroids and β-blockers such as pro-







































































common national German guideline by dermatologists, 
pediatric surgeons, pediatricians, pediatric dermatolo-
gists, and oral- and maxillofacial surgeons on the man-
agement of infantile hemangioma, use of interferons and 
vincristine in infantile hemangioma should be aban-
doned due to severe potential side effects [29]. Systemic 
steroids may only be used in life-threatening or refrac-
tory situations and should be applied for 14 days maxi-
mum [29]. In our cohort, oral propranolol (usually 2 mg/
kg) proved effective – as judged by caregivers – in treat-
ment of facial hemangioma.
We acknowledge a few limitations to our study: First, 
its retrospective design may have led to recall bias. Yet, 
the patients’ young age and administration of question-
naires to caregivers and to child neurologists should rem-
edy this. Second, the small number of cases results in lim-
ited power and increases the likelihood for spurious as-
sociations. Moreover, only 10 of 19 patients with PHACE 
syndrome consented to provide full clinical data for fur-
ther analysis. Substantial differences in prevalence rates 
between Switzerland and Germany and Austria were 
seen, most likely caused by systematic underreporting in 
Germany and Austria. Nevertheless, results from our co-
hort are in line with findings from the literature, indicat-
ing that our data are nonbiased and that they are repre-
sentative of the “true” general pediatric PHACE syn-
drome population.
Conclusions
To our knowledge, our study is the first to report prev-
alence rates of PHACE syndrome in Europe, demonstrat-
ing that PHACE syndrome is more prevalent than previ-
ous reports have indicated. Our data highlight the wide 
clinical spectrum of PHACE syndrome and show that af-
fected patients require management by a multidisci-
plinary team. The clinical observation of an association 
between the size of facial hemangioma and extent of or-
gan involvement warrants further investigation.
Appendix
Questionnaires as used in this study: Translated and modified 
versions of questionnaires originally developed by the Interna-
tional PHACE Registry and Repository (families’ version and 
physicians’ version): see online supplementary material (www. 
karger.com/doi/10.1159/000508187).
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